Veterinary Neurodegenerative Disease Diagnostics Market Size, Share and Growth Outlook 2026: By Diagnostic Test Type, By Product Type, By Animal Type, By Indication, By End User, Companies to 2034
The global Veterinary Neurodegenerative Disease Diagnostics Market size is forecast to increase from $371.83 Million in 2026 to $667.61 Million in 2034 at a CAGR of 7.59% between 2026 and 2034.
The Veterinary Neurodegenerative Disease Diagnostics market report provides detailed analysis and outlook of Veterinary Neurodegenerative Disease Diagnostics segments including By Diagnostic Test Type (Imaging Technologies, Biomarker Diagnostic Tests, Other Diagnostic Methods), By Product Type (Consumables, Reagents and Kits, Equipment and Instruments), By Animal Type (Companion Animals, Livestock / Production Animals ), By Indication (Cognitive Dysfunction, Cerebellar Abiotrophy, Spongiform Encephalopathies, Other Indications), By End User (Veterinary Hospitals and Clinics, Veterinary Diagnostic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Veterinary Neurodegenerative Disease Diagnostics Industry Overview
Advanced Diagnostics Are Improving Detection of Neurological Disorders in Companion Animals.
The veterinary neurodegenerative disease diagnostics industry is evolving as increasing numbers of aging companion animals require earlier detection and long-term monitoring of neurological disorders, spinal degeneration, cognitive dysfunction, and related chronic diseases. Veterinary practices are adopting advanced diagnostic technologies that combine artificial intelligence, digital imaging, point-of-care laboratory testing, and specialist consultation to improve diagnostic accuracy while enabling earlier clinical intervention. Manufacturers are developing integrated diagnostic ecosystems that support comprehensive neurological assessment through hematology, imaging, telepathology, and continuous disease monitoring, strengthening clinical decision-making across general practice and specialty veterinary medicine.
Artificial Intelligence and Advanced Imaging Are Enhancing Clinical Evaluation.
The industry is increasingly integrating intelligent diagnostic platforms capable of generating comprehensive clinical information from multiple diagnostic modalities. Artificial intelligence, microfluidics, and high-resolution imaging are improving the ability of veterinarians to identify neurological abnormalities and age-related disease progression during routine clinical evaluations. This trend is demonstrated by Zoetis through expansion of the Vetscan OptiCell™ point-of-care hematology analyzer, which combines artificial intelligence with advanced viscoelastic focusing microfluidic technology to evaluate 24 hematological parameters, including Cellular Hemoglobin Concentration Mean, supporting assessment of chronic disease, neurological abnormalities, and metabolic changes in aging companion animals. Complementing laboratory diagnostics, IDEXX Laboratories introduced the ImageVue® DR50 Plus digital radiography system, providing high-definition, low-dose imaging that enables clinicians to evaluate cranial structures, spinal alignment, and surrounding soft tissues for neurovascular defects and degenerative neurological conditions directly within veterinary clinics.
Digital Specialist Networks Are Expanding Access to Neurological Expertise.
The veterinary neurodegenerative disease diagnostics industry is increasingly leveraging telemedicine and specialist consultation platforms to improve diagnostic confidence and long-term disease management. Digital pathology services and educational initiatives are helping general practitioners deliver more comprehensive neurological care while facilitating collaboration with board-certified specialists. This evolution is illustrated by Heska Corporation through the introduction of HeskaView Specialty Services, an integrated telecytology platform that connects veterinary practitioners with board-certified clinical pathologists while supporting specialized educational programs in veterinary neurology. The platform strengthens local neurological screening, improves diagnostic interpretation, and facilitates structured long-term monitoring strategies for companion animals affected by progressive neurodegenerative disorders, reflecting the industry's broader transition toward collaborative, technology-enabled neurological diagnostics.
Veterinary Neurodegenerative Disease Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Veterinary Neurodegenerative Disease Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., IDEXX Laboratories, Inc., Virbac, Merck & Co., Inc, Antech Diagnostics, Inc. (Mars Veterinary Health), Life Diagnostics, Inc., Acuvet Biotech, MI:RNA Diagnostics Ltd, Mercodia AB, Avacta Animal Health Limited. The Veterinary Neurodegenerative Disease Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Veterinary Neurodegenerative Disease Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Veterinary Neurodegenerative Disease Diagnostics industry include- Zoetis Inc., IDEXX Laboratories, Inc., Virbac, Merck & Co., Inc, Antech Diagnostics, Inc. (Mars Veterinary Health), Life Diagnostics, Inc., Acuvet Biotech, MI:RNA Diagnostics Ltd, Mercodia AB, Avacta Animal Health Limited. The Veterinary Neurodegenerative Disease Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Veterinary Neurodegenerative Disease Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Veterinary Neurodegenerative Disease Diagnostics market remains one of the strongest-performing segments in the country.
The US Veterinary Neurodegenerative Disease Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Veterinary Neurodegenerative Disease Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Veterinary Neurodegenerative Disease Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Veterinary Neurodegenerative Disease Diagnostics markets
Canada's strong Veterinary Neurodegenerative Disease Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Veterinary Neurodegenerative Disease Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Veterinary Neurodegenerative Disease Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Veterinary Neurodegenerative Disease Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Veterinary Neurodegenerative Disease Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Veterinary Neurodegenerative Disease Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Veterinary Neurodegenerative Disease Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Veterinary Neurodegenerative Disease Diagnostics sales through 2034
France Veterinary Neurodegenerative Disease Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Veterinary Neurodegenerative Disease Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Veterinary Neurodegenerative Disease Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Veterinary Neurodegenerative Disease Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Veterinary Neurodegenerative Disease Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Veterinary Neurodegenerative Disease Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Veterinary Neurodegenerative Disease Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Veterinary Neurodegenerative Disease Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Veterinary Neurodegenerative Disease Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Veterinary Neurodegenerative Disease Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Veterinary Neurodegenerative Disease Diagnostics Market Segmentation
By Diagnostic Test Type
Imaging Technologies
Biomarker Diagnostic Tests
Other Diagnostic Methods
By Product Type
Consumables, Reagents and Kits
Equipment and Instruments
By Animal Type
Companion Animals
Livestock / Production Animals
By Indication
Cognitive Dysfunction
Cerebellar Abiotrophy
Spongiform Encephalopathies
Other Indications
By End User
Veterinary Hospitals and Clinics
Veterinary Diagnostic Laboratories
Leading Companies in Veterinary Neurodegenerative Disease Diagnostics Industry (2026)
Zoetis Inc.
IDEXX Laboratories, Inc.
Virbac
Merck & Co., Inc
Antech Diagnostics, Inc. (Mars Veterinary Health)
Life Diagnostics, Inc.
Acuvet Biotech
MI:RNA Diagnostics Ltd
Mercodia AB
Avacta Animal Health Limited
Countries Included
The Veterinary Neurodegenerative Disease Diagnostics market report provides detailed analysis and outlook of Veterinary Neurodegenerative Disease Diagnostics segments including By Diagnostic Test Type (Imaging Technologies, Biomarker Diagnostic Tests, Other Diagnostic Methods), By Product Type (Consumables, Reagents and Kits, Equipment and Instruments), By Animal Type (Companion Animals, Livestock / Production Animals ), By Indication (Cognitive Dysfunction, Cerebellar Abiotrophy, Spongiform Encephalopathies, Other Indications), By End User (Veterinary Hospitals and Clinics, Veterinary Diagnostic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Veterinary Neurodegenerative Disease Diagnostics Industry Overview
Advanced Diagnostics Are Improving Detection of Neurological Disorders in Companion Animals.
The veterinary neurodegenerative disease diagnostics industry is evolving as increasing numbers of aging companion animals require earlier detection and long-term monitoring of neurological disorders, spinal degeneration, cognitive dysfunction, and related chronic diseases. Veterinary practices are adopting advanced diagnostic technologies that combine artificial intelligence, digital imaging, point-of-care laboratory testing, and specialist consultation to improve diagnostic accuracy while enabling earlier clinical intervention. Manufacturers are developing integrated diagnostic ecosystems that support comprehensive neurological assessment through hematology, imaging, telepathology, and continuous disease monitoring, strengthening clinical decision-making across general practice and specialty veterinary medicine.
Artificial Intelligence and Advanced Imaging Are Enhancing Clinical Evaluation.
The industry is increasingly integrating intelligent diagnostic platforms capable of generating comprehensive clinical information from multiple diagnostic modalities. Artificial intelligence, microfluidics, and high-resolution imaging are improving the ability of veterinarians to identify neurological abnormalities and age-related disease progression during routine clinical evaluations. This trend is demonstrated by Zoetis through expansion of the Vetscan OptiCell™ point-of-care hematology analyzer, which combines artificial intelligence with advanced viscoelastic focusing microfluidic technology to evaluate 24 hematological parameters, including Cellular Hemoglobin Concentration Mean, supporting assessment of chronic disease, neurological abnormalities, and metabolic changes in aging companion animals. Complementing laboratory diagnostics, IDEXX Laboratories introduced the ImageVue® DR50 Plus digital radiography system, providing high-definition, low-dose imaging that enables clinicians to evaluate cranial structures, spinal alignment, and surrounding soft tissues for neurovascular defects and degenerative neurological conditions directly within veterinary clinics.
Digital Specialist Networks Are Expanding Access to Neurological Expertise.
The veterinary neurodegenerative disease diagnostics industry is increasingly leveraging telemedicine and specialist consultation platforms to improve diagnostic confidence and long-term disease management. Digital pathology services and educational initiatives are helping general practitioners deliver more comprehensive neurological care while facilitating collaboration with board-certified specialists. This evolution is illustrated by Heska Corporation through the introduction of HeskaView Specialty Services, an integrated telecytology platform that connects veterinary practitioners with board-certified clinical pathologists while supporting specialized educational programs in veterinary neurology. The platform strengthens local neurological screening, improves diagnostic interpretation, and facilitates structured long-term monitoring strategies for companion animals affected by progressive neurodegenerative disorders, reflecting the industry's broader transition toward collaborative, technology-enabled neurological diagnostics.
Veterinary Neurodegenerative Disease Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Veterinary Neurodegenerative Disease Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Zoetis Inc., IDEXX Laboratories, Inc., Virbac, Merck & Co., Inc, Antech Diagnostics, Inc. (Mars Veterinary Health), Life Diagnostics, Inc., Acuvet Biotech, MI:RNA Diagnostics Ltd, Mercodia AB, Avacta Animal Health Limited. The Veterinary Neurodegenerative Disease Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Veterinary Neurodegenerative Disease Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Veterinary Neurodegenerative Disease Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Veterinary Neurodegenerative Disease Diagnostics companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Veterinary Neurodegenerative Disease Diagnostics markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Veterinary Neurodegenerative Disease Diagnostics industry include- Zoetis Inc., IDEXX Laboratories, Inc., Virbac, Merck & Co., Inc, Antech Diagnostics, Inc. (Mars Veterinary Health), Life Diagnostics, Inc., Acuvet Biotech, MI:RNA Diagnostics Ltd, Mercodia AB, Avacta Animal Health Limited. The Veterinary Neurodegenerative Disease Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Veterinary Neurodegenerative Disease Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Veterinary Neurodegenerative Disease Diagnostics market remains one of the strongest-performing segments in the country.
The US Veterinary Neurodegenerative Disease Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Veterinary Neurodegenerative Disease Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Veterinary Neurodegenerative Disease Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Veterinary Neurodegenerative Disease Diagnostics markets
Canada's strong Veterinary Neurodegenerative Disease Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Veterinary Neurodegenerative Disease Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Veterinary Neurodegenerative Disease Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Veterinary Neurodegenerative Disease Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Veterinary Neurodegenerative Disease Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Veterinary Neurodegenerative Disease Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Veterinary Neurodegenerative Disease Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Veterinary Neurodegenerative Disease Diagnostics sales through 2034
France Veterinary Neurodegenerative Disease Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Veterinary Neurodegenerative Disease Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Veterinary Neurodegenerative Disease Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Veterinary Neurodegenerative Disease Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Veterinary Neurodegenerative Disease Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Veterinary Neurodegenerative Disease Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Veterinary Neurodegenerative Disease Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Veterinary Neurodegenerative Disease Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Veterinary Neurodegenerative Disease Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Veterinary Neurodegenerative Disease Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Veterinary Neurodegenerative Disease Diagnostics Market Segmentation
By Diagnostic Test Type
Imaging Technologies
Biomarker Diagnostic Tests
Other Diagnostic Methods
By Product Type
Consumables, Reagents and Kits
Equipment and Instruments
By Animal Type
Companion Animals
Livestock / Production Animals
By Indication
Cognitive Dysfunction
Cerebellar Abiotrophy
Spongiform Encephalopathies
Other Indications
By End User
Veterinary Hospitals and Clinics
Veterinary Diagnostic Laboratories
Leading Companies in Veterinary Neurodegenerative Disease Diagnostics Industry (2026)
Zoetis Inc.
IDEXX Laboratories, Inc.
Virbac
Merck & Co., Inc
Antech Diagnostics, Inc. (Mars Veterinary Health)
Life Diagnostics, Inc.
Acuvet Biotech
MI:RNA Diagnostics Ltd
Mercodia AB
Avacta Animal Health Limited
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Veterinary Neurodegenerative Disease Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Veterinary Neurodegenerative Disease Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Veterinary Neurodegenerative Disease Diagnostics Markets in 2026
3.2. Global Historic and Forecast Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Veterinary Neurodegenerative Disease Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Veterinary Neurodegenerative Disease Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Veterinary Neurodegenerative Disease Diagnostics Value Chain
CHAPTER 4- VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Veterinary Neurodegenerative Disease Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Diagnostic Test Type
Imaging Technologies
Biomarker Diagnostic Tests
Other Diagnostic Methods
By Product Type
Consumables, Reagents and Kits
Equipment and Instruments
By Animal Type
Companion Animals
Livestock / Production Animals
By Indication
Cognitive Dysfunction
Cerebellar Abiotrophy
Spongiform Encephalopathies
Other Indications
By End User
Veterinary Hospitals and Clinics
Veterinary Diagnostic Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
7.6. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
7.7. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Veterinary Neurodegenerative Disease Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Veterinary Neurodegenerative Disease Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 8- EUROPE VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
8.6. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
8.7. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Veterinary Neurodegenerative Disease Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Veterinary Neurodegenerative Disease Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Veterinary Neurodegenerative Disease Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Veterinary Neurodegenerative Disease Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Veterinary Neurodegenerative Disease Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 9- ASIA PACIFIC VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
9.6. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
9.7. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Veterinary Neurodegenerative Disease Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Veterinary Neurodegenerative Disease Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Veterinary Neurodegenerative Disease Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Veterinary Neurodegenerative Disease Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Veterinary Neurodegenerative Disease Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
10.6. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
10.7. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Veterinary Neurodegenerative Disease Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Veterinary Neurodegenerative Disease Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Veterinary Neurodegenerative Disease Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Veterinary Neurodegenerative Disease Diagnostics Industry
Zoetis Inc.
IDEXX Laboratories, Inc.
Virbac
Merck & Co., Inc
Antech Diagnostics, Inc. (Mars Veterinary Health)
Life Diagnostics, Inc.
Acuvet Biotech
MI:RNA Diagnostics Ltd
Mercodia AB
Avacta Animal Health Limited
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Veterinary Neurodegenerative Disease Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Veterinary Neurodegenerative Disease Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Veterinary Neurodegenerative Disease Diagnostics Markets in 2026
3.2. Global Historic and Forecast Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Veterinary Neurodegenerative Disease Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Veterinary Neurodegenerative Disease Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Veterinary Neurodegenerative Disease Diagnostics Value Chain
CHAPTER 4- VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Veterinary Neurodegenerative Disease Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Diagnostic Test Type
Imaging Technologies
Biomarker Diagnostic Tests
Other Diagnostic Methods
By Product Type
Consumables, Reagents and Kits
Equipment and Instruments
By Animal Type
Companion Animals
Livestock / Production Animals
By Indication
Cognitive Dysfunction
Cerebellar Abiotrophy
Spongiform Encephalopathies
Other Indications
By End User
Veterinary Hospitals and Clinics
Veterinary Diagnostic Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
7.6. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
7.7. North America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Veterinary Neurodegenerative Disease Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Veterinary Neurodegenerative Disease Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 8- EUROPE VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
8.6. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
8.7. Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Veterinary Neurodegenerative Disease Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Veterinary Neurodegenerative Disease Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Veterinary Neurodegenerative Disease Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Veterinary Neurodegenerative Disease Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Veterinary Neurodegenerative Disease Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 9- ASIA PACIFIC VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
9.6. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
9.7. Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Veterinary Neurodegenerative Disease Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Veterinary Neurodegenerative Disease Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Veterinary Neurodegenerative Disease Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Veterinary Neurodegenerative Disease Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Veterinary Neurodegenerative Disease Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
10.6. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
10.7. South and Central America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Veterinary Neurodegenerative Disease Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Veterinary Neurodegenerative Disease Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA VETERINARY NEURODEGENERATIVE DISEASE DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Veterinary Neurodegenerative Disease Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Veterinary Neurodegenerative Disease Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Veterinary Neurodegenerative Disease Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Veterinary Neurodegenerative Disease Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Veterinary Neurodegenerative Disease Diagnostics Industry
Zoetis Inc.
IDEXX Laboratories, Inc.
Virbac
Merck & Co., Inc
Antech Diagnostics, Inc. (Mars Veterinary Health)
Life Diagnostics, Inc.
Acuvet Biotech
MI:RNA Diagnostics Ltd
Mercodia AB
Avacta Animal Health Limited
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
